Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare RIIF vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Resolution Gbl Listed Infra Fund - Active ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are RIIF and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

RIIF

DRUG

Popularity

N/A

Low

Pearlers invested

0

64

Median incremental investment

$0

$990.50

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,963.48

Average age group

N/A

26 - 35


Key Summary

RIIF

DRUG

Strategy

RIIF.AX was created on 2024-08-12 by Resolution Capital. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to achieve an annual total return that exceeds the total return of the Benchmark after fees on a rolling 3-year basis

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Resolution Gbl Listed Infra Fund - Active ETF (100 %)

BRL - BRAZILIAN REAL (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

CHF - SWISS FRANC (0 %)

Top 3 industries

Other (77.10 %)

Communication Services (33.53 %)

Health Care (22.75 %)

Top 3 countries

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0 %

0.57 %


Key Summary

RIIF

DRUG

Issuer

Resolution Capital

BetaShares

Tracking index

FTSE Developed Core Infrastructure 50/50 Index - AUD - Benchmark TR Net Hedged

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0 %

0.57 %

Price

$1.09

$7.64

Size

N/A

$162.958 million

10Y return

N/A

N/A

Annual dividend/โ€Šdistribution yield (5Y)

0.17 %

1.89 %

Market

ASX

ASX

First listed date

24/03/2025

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

RIIF

DRUG

Popularity

N/A

Low

Pearlers invested

0

64

Median incremental investment

$0

$990.50

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,963.48

Average age group

N/A

26 - 35


Pros and Cons

RIIF

DRUG

Pros

  • Lower management fee

  • Higher exposure to US market

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower price growth

  • Lower distribution yield

  • Higher management fee

RIIF

DRUG

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield